Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05165485 · ClinicalTrials.gov registry record · Phase 4
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
A Phase 4 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 404
- Enrollment target
NCT05165485: Completed Phase 4 study, sponsored by Theravance Biopharma.
NCT05165485 is a Phase 4 study that has completed, run by Theravance Biopharma. The registered enrollment target is 404 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05165485, a Phase 4 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 404 participants
- Enrollment target
Study Summary
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
Primary Outcome
Change from baseline in forced expiratory volume in one second (FEV1) at trough on Day 85
Interventions
- DRUG Tiotropium
- DRUG Revefenacin
- DRUG Revefenacin Placebo
- DRUG Tiotropium Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2022-01-07 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 4 |
What the finished NCT05165485 record still lists
NCT05165485 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 4 interventions - of which Tiotropium is the first listed.
NCT05165485 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05165485 about?
NCT05165485 is a clinical study titled "Phase 4 COPD and Suboptimal Inspiratory Flow Rate". Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
What is the current status of trial NCT05165485?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 404 participants. The study started on 2022-01-07. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT05165485?
The interventions under investigation include: Tiotropium (DRUG), Revefenacin (DRUG), Revefenacin Placebo (DRUG), Tiotropium Placebo (DRUG).
Who is sponsoring clinical trial NCT05165485?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05165485's enrollment target sits among peer trials
404 209th of 2000 higher than 1,791 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI